Clinical Trials How to do them Basil S
Clinical Trials: How to do them? Basil S. Lewis, MD, FRCP, FACC, FESC Professor of Medicine Haifa, Israel Chairman-Elect, ESC WG on Cardiovascular Pharmacotherapy
Trials that Changed Medicine: CHF 1987 Lady Davis Carmel Cardiovascular Center
ACS: Cumulative Hazard CURE Rates for CV Death/MI/Stroke Cumulative Hazard Rates Placebo Clopidogrel p <0. 001 RRR=20% 0 No of Pts 3 6 9 12 Months of Follow-up Plac 6303 5780 4664 3600 2388 Clop 6259 5866 4779 3644 2418 ACC, Mar 2001
AF: Stroke or Systemic Embolism Non-inferiority Superiority p-value Dabigatran 110 vs. Warfarin Dabigatran 150 vs. Warfarin <0. 001 0. 34 <0. 001 Margin = 1. 46 0. 50 ESC, 2009 0. 75 Dabigatran better 1. 00 1. 25 HR (95% CI) 1. 50 Warfarin better
Your Clinical Trial: Trial Objectives • Objectives should be relevant and important • Objectives should be clear and well defined • • Do ACE-inhibitors improve survival in HF patients? Is DAPT superior to aspirin alone? Is dabigatran non-inferior to warfarin? Is dabigatran superior to warfarin?
Methodology and Trial Design Questions • Randomized controlled trial (RCT)? • Single or double blinding? • Subgroup stratification? • Choice of primary outcome? • Predefined secondary outcomes?
Trial Endpoints • Clear endpoints • Primary endpoint • Secondary endpoints • Clinical endpoints vs surrogate endpoints/mechanistic endpoints • Example • Do new lipid lowering drugs reduce LDL? (surrogate) • Comparison with old Rx • What components do they alter? (mechanistic) • Do the changes translate into meaningful clinical benefit? (the real issue) • What are the side effects, safety issues, price to pay?
Primary Endpoint • Primary endpoint • Choose carefully • Composite endpoints capture the effect of a new treatment on disease burden • ACS trials: Death, non-fatal MI, non-fatal stroke • Heart failure: Death, hospitalization for heart failure • AF trials (SPAF): stroke, systemic embolism • Wider composite end-point may increase power but could dilute the effect and lose the study! (TRACER-ACS example) • Co-primary endpoint may be a useful solution
Secondary Endpoints • Secondary endpoints • Examine in more detail components of the primary and other expected or exploratory findings • Must be predefined • How many? • Not valid if primary end-point is not met? • The CURRENT-OASIS 8 study example
(A) Survival curves for traditional composite. Jeffrey A. Bakal et al. Eur Heart J 2015; 36: 385 -392 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2014. For permissions please email: journals. permissions@oup. com
Factorial Designs? Added Value • Opportunity to study extra question • Little extra cost • Examples • ISIS-4 studied ACE-I in acute MI • ORIGIN studied lantus insulin in diabetes • HOPE 3 is looking at LDL cholesterol lowering + role of Mg + role of Omega 3 + BP control
HOPE-3: 2 x 2 Factorial Design N = 14, 000 people at intermediate risk for CVD Candesartan/HCT (Atacand plus 16/12. 5 mg) Placebo Rosuvastatin (10 mg) Rosuvastatin + Candesartan/HCT Rosuvastatin + Placebo Candesartan/HCT+ Placebo Follow-up for an average of 6 years
The Site – Patients and Staff • Site should have access to appropriate patients • Inpatient study (eg ACS, Acute HF) • Outpatient study • Referral base • Properly trained staff • PI, SI’s • Research co-ordinator(s) – according to study needs • • Nurse Biotechnician Secretarial Other • All personnel need to be trained in GCP
The Site – Adequate Facilities • Site facilities • Working space • Team and monitors • Storage space • Drug (IP), trial files, patient files • Storage facilities • Store IP – Pharmacy? Research unit? • Refrigeration for IP • Refrigeration for biologic samples - -20? -80? • Equipment • Routine equipment available - EKG, BP, scales, tapes, other • Local labs may be required
The Site – Administrative and communication • Electronic communication essential for most trials • Email, fax, scanners • Web communication • CRF and data transfer usually depends on Electronic data capture (EDC) • Connection availability and speed (institutional firewalls can be challenging) • Site training • All personnel need to be trained in communication with discreet user IDs • Paper based research trials for smaller/local trials
Clinical Trials: Site Enrollment • Enrollment expectations and commitment • Realistic commitment • Competition for patients and resources must be taken into account • Track record • Financial viability
Clinical Trials: Financing • Non- funded • Institutional, health system funding • Research grant • Contract research with a sponsor • University sponsored • Commercial entity or industry sponsored
Ethics Committee • The ethics committee (EC; IRB; “Helsinki” committee) is responsible for ensuring patient safety • Composition of IRB • • • Scientists and researchers Experts in the field Public representative(s) Institutional administrators Legal opinion
Role of the Ethics Committee • The ethics committee is responsible for ensuring patient safety Ethics of the protocol Competence of the investigators and staff Informed consent language and process Ensure that there is an updated investigator brochure with proper information for investigators • Reviewing trial progress • • Number of patients in trial Adverse and serious adverse events Input from DSMB Protocol violations • Approval is usually renewable on an annual basis after review of trial progress
Role of a Research Organization • For most large-scale trials, a professional research organization is mandated by the sponsor to manage the trial • • • Site selection and feasibility Contracts Submissions to IRBs Initiation visits Monitoring • Ensure data authenticity by checking source data • Ensure data completeness • Problem solving
Contract Research Organization (CRO) vs Academic Research Organization (ARO) • CRO Very professional Independent Dedicated Attention to everything • Business oriented • Expensive • • • ARO • Scientific and professional • Independent • Lesser dedication and assistance to sites • Cheaper
Join the ESC Working Group on Cardiovascular Pharmacotherapy Membership is FREE! www. escardio. org/pharmacology
- Slides: 22